83.55

3.47% 2.80

After Hours: 83.55

Apogee Therapeutics Inc (APGE)

Overview News Price History Financials Discussions Forecast

Apogee Therapeutics Inc stock is traded at $83.55, with a volume of 567.88K. It is up +3.47% in the last 24 hours and down -0.94% over the past month. Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.

Previous Close:

$80.75

Open:

$80.63

24h Volume:

567.88K

Relative Volume:

0.60

Market Cap:

$6.29B

Revenue:

Net Income/Loss:

$-255.84M

P/E Ratio:

-19.82

EPS:

-4.2149

Net Cash Flow:

$-232.60M

1W Performance:

-3.38%

1M Performance:

-0.94%

6M Performance:

+55.01%

1Y Performance:

+108.25%

1-Day Range:

$80.52

$85.45

1-Week Range:

$80.52

$87.69

52-Week Range:

$34.34

$95.31

Apogee Therapeutics Inc Stock (APGE) Company Profile

Name

Apogee Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (622)

Phone

650-394-5230

Address

221 CRESCENT ST., WALTHAM

Employee

261

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

APGE's Discussions on Twitter

Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APGE Apogee Therapeutics Inc	83.55	6.08B	0	-255.84M	-232.60M	-4.2149
VRTX Vertex Pharmaceuticals Inc	429.85	107.83B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	709.21	73.54B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	811.09	48.72B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	297.93	39.51B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.14	32.66B	5.36B	287.73M	924.18M	2.5229

Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Hold
Jan-22-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jan-07-26	Initiated	Wolfe Research	Peer Perform
Dec-17-25	Initiated	Stephens	Overweight
Dec-10-25	Initiated	Deutsche Bank	Buy
Nov-03-25	Initiated	Craig Hallum	Buy
Oct-21-25	Initiated	Mizuho	Outperform
Sep-25-25	Initiated	RBC Capital Mkts	Outperform
Jul-07-25	Reiterated	BTIG Research	Buy
Mar-13-25	Initiated	Citigroup	Buy
Nov-25-24	Initiated	Canaccord Genuity	Buy
May-10-24	Initiated	BofA Securities	Buy
Dec-20-23	Initiated	BTIG Research	Buy
Aug-08-23	Initiated	Guggenheim	Buy
Aug-08-23	Initiated	Jefferies	Buy
Aug-08-23	Initiated	Stifel	Buy
Aug-08-23	Initiated	TD Cowen	Outperform
Aug-08-23	Initiated	Wedbush	Outperform

View All

Apogee Therapeutics Inc Stock (APGE) Latest News

May 04, 2026

CFO of Apogee Therapeutics (APGE) sells 2,000 shares under 10b5-1 plan - Stock Titan

May 04, 2026

May 02, 2026

Apogee Therapeutics (NASDAQ:APGE) Upgraded to Strong-Buy at Rothschild & Co Redburn - MarketBeat

May 02, 2026

Jennison Associates LLC Invests $43.68 Million in Apogee Therapeutics Inc. $APGE - MarketBeat

May 02, 2026

May 01, 2026

Insider sales reported for APGE (NASDAQ: APGE) — five 2,000-share trades - Stock Titan

May 01, 2026

Rothschild & Co Redburn Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $140 - Moomoo

May 01, 2026

Pictet Asset Management Holding SA Takes $23.62 Million Position in Apogee Therapeutics Inc. $APGE - MarketBeat

May 01, 2026

Rothschild Redburn initiates Apogee stock with buy on AD therapy - Investing.com UK

May 01, 2026

Rothschild Redburn initiates Apogee stock with buy on AD therapy By Investing.com - Investing.com India

May 01, 2026

Rothschild & Co initiates coverage of Apogee Therapeutics (APGE) with buy recommendation - MSN

May 01, 2026

Apr 29, 2026

Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN

Apr 29, 2026

APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN

Apr 29, 2026

Apogee Therapeutics (APGE) Study result Summary - Quartr

Apr 29, 2026

Apogee Therapeutics (APGE) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary - Quartr

Apr 29, 2026

Apr 27, 2026

Apogee Therapeutics Stock Surges as Investors Bet on Immunology Breakthrough - HarianBasis.co

Apr 27, 2026